MX346362B - Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. - Google Patents

Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.

Info

Publication number
MX346362B
MX346362B MX2012005222A MX2012005222A MX346362B MX 346362 B MX346362 B MX 346362B MX 2012005222 A MX2012005222 A MX 2012005222A MX 2012005222 A MX2012005222 A MX 2012005222A MX 346362 B MX346362 B MX 346362B
Authority
MX
Mexico
Prior art keywords
binding sites
methods
therapeutic agents
rgd binding
cellular adhesion
Prior art date
Application number
MX2012005222A
Other languages
English (en)
Other versions
MX2012005222A (es
Inventor
Park John
John Mackel Michael
Original Assignee
Allegro Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allegro Pharmaceuticals Inc * filed Critical Allegro Pharmaceuticals Inc *
Publication of MX2012005222A publication Critical patent/MX2012005222A/es
Publication of MX346362B publication Critical patent/MX346362B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Surgery (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención se refiere a compuestos que comprenden ácido R-G-cistéico (es decir, R-G-NH-CH (CH2-SO3H) COOH o Arg-GIy-NH-CH (CH2-SO3H) COOH) y sus derivados, incluyendo sus sales farmacéuticas aceptables, hidratos, estereoisómeros, multímeros, formas cíclicas, formas lineares, conjugados-fármaco, pro-fármacos y sus derivados. También se describen métodos para producir y usar tales compuestos incluyendo los métodos para inhibir la adhesión celular a los sitios de enlace RGD o suministrar otros agentes de diagnóstico o terapéuticos a los sitios de enlace RGD en sujetos humanos o animales.
MX2012005222A 2009-11-10 2010-11-10 Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd. MX346362B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25974809P 2009-11-10 2009-11-10
PCT/US2010/056277 WO2011060104A2 (en) 2009-11-10 2010-11-10 Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites

Publications (2)

Publication Number Publication Date
MX2012005222A MX2012005222A (es) 2012-08-15
MX346362B true MX346362B (es) 2017-03-15

Family

ID=43992385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005222A MX346362B (es) 2009-11-10 2010-11-10 Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.

Country Status (17)

Country Link
US (5) US9018352B2 (es)
EP (2) EP2504035B8 (es)
JP (3) JP5912082B2 (es)
KR (2) KR101988362B1 (es)
CN (3) CN105106934A (es)
AU (2) AU2010319559A1 (es)
BR (1) BR112012011731A2 (es)
CA (1) CA2780243C (es)
ES (1) ES2730927T3 (es)
HK (1) HK1218075A1 (es)
IL (2) IL219701A (es)
MX (1) MX346362B (es)
NZ (2) NZ599899A (es)
PL (1) PL2504035T3 (es)
RU (1) RU2642625C2 (es)
WO (1) WO2011060104A2 (es)
ZA (1) ZA201204209B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060104A2 (en) 2009-11-10 2011-05-19 Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
US11673914B2 (en) * 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
EP2707036A4 (en) * 2011-05-09 2015-03-18 Allegro Pharmaceuticals Inc INTEGRIN RECEPTOR ANTAGONISTS AND METHOD FOR THEIR USE
US20160022491A1 (en) * 2014-07-24 2016-01-28 Strathspey Crown Holdings, LLC Interventional Treatments for VitreoRetinal-Interface Syndromes
WO2017153567A1 (en) 2016-03-10 2017-09-14 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
WO2017170626A1 (ja) * 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤
CN109922794B (zh) 2016-08-18 2022-11-04 特洛伊.布雷莫 使用脂质体构建体将尿素递送至黄斑和视网膜的细胞
CA3050904A1 (en) * 2017-01-19 2018-07-26 Hampar L. Karageozian Therapeutic and neuroprotective peptides
JP7280619B2 (ja) * 2017-06-19 2023-05-24 アレグロ ファーマシューティカルズ エルエルシー ペプチド組成物
EP3941586A4 (en) * 2019-03-21 2023-03-15 Cortexyme, Inc. ARGININE GINGIPAIN INHIBITORS
EP3958915A4 (en) * 2019-04-22 2023-01-11 Allegro Ophthalmics, LLC COMPOSITIONS AND METHODS USABLE FOR THE TREATMENT OF DRY EYE
CN110669142B (zh) * 2019-09-30 2021-10-12 湖南农业大学 融合rgd的猪圆环病毒2型病毒样颗粒、突变型感染性克隆及其制备方法和应用
JP2023516431A (ja) * 2020-03-06 2023-04-19 アレグロ ファーマシューティカルズ エルエルシー ミトコンドリア機能の改善または機能障害の軽減のための治療
TWI776410B (zh) * 2021-03-02 2022-09-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其用於治療乾眼症之用途
WO2022234536A1 (en) * 2021-05-06 2022-11-10 Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4Tec) - Associação Hydrogel based on hyaluronic acid polymer for use for treating solid tumours
CN113577246B (zh) * 2021-08-02 2023-11-03 赛克赛斯生物科技股份有限公司 一种预防瘢痕粘连的组合物、术后防粘连材料及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4661111A (en) * 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) * 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
WO1994015953A1 (en) 1993-01-04 1994-07-21 The Regents Of The University Of California Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
AU6156294A (en) 1993-03-03 1994-09-26 Teijin Limited Physiologically active peptide
AU6415894A (en) * 1993-03-29 1994-10-24 Du Pont Merck Pharmaceutical Company, The Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia
US6346604B1 (en) 1995-10-31 2002-02-12 Takeda Chemical Industries, Inc. Method for controlling conformation of cyclopentapeptide
EP0767674A4 (en) 1994-06-29 1999-06-16 Texas Biotechnology Corp METHOD FOR INHIBITING THE BINDING OF INTEGRIN ALPHA 4 BETA 1 TO VCAM-1 OR FIBRONECTIN
JPH08119991A (ja) * 1994-10-24 1996-05-14 Otsuka Pharmaceut Factory Inc ペプチド誘導体及びｉｌ−１産生抑制剤
US6551574B2 (en) * 1995-06-07 2003-04-22 Rhomed Incorporated Tuftsin metallopeptide analogs and uses thereof
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
WO1997045137A1 (en) 1996-05-31 1997-12-04 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
SK163598A3 (en) 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
US6331285B1 (en) * 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
AU6141498A (en) 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US20030170250A1 (en) * 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
AU4057799A (en) * 1998-05-29 1999-12-20 St. Marianna University School Of Medicine T cell antigen receptor sequences specific to arthrosis deformans
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
BR0007532A (pt) * 1999-01-13 2001-11-20 Univ New York State Res Found Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
US7070936B1 (en) * 1999-01-13 2006-07-04 The Research Foundation Of State University Of New York Method for designing protein kinase inhibitors
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7002989B2 (en) * 2000-04-10 2006-02-21 At&T Corp. Method and apparatus for S.I.P./H. 323 interworking
WO2002063017A2 (en) 2001-02-05 2002-08-15 Trigen Limited Integrin-binding chimeras
WO2002067972A1 (en) * 2001-02-28 2002-09-06 Duke University Method of inducing vitreous detachment
JP2002326949A (ja) * 2001-05-02 2002-11-15 Kansai Tlo Kk 免疫賦活剤
US7906102B2 (en) * 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
AU2002363253A1 (en) 2001-11-01 2003-05-12 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
MXPA05007329A (es) 2003-01-07 2005-09-30 Yeda Res & Dev Vacuna de gotas oculares que contiene copolimero 1 para inmunizacion terapeutica.
CN1849132A (zh) 2003-09-10 2006-10-18 伦敦大学国王学院 调节神经元生长的化合物以及它们的用途
CN101068553A (zh) * 2004-06-04 2007-11-07 斯克里普斯研究学院 用于治疗新生血管性疾病的组合物和方法
WO2006017619A2 (en) 2004-08-06 2006-02-16 The Regents Of The University Of California Receptor-binding cyclic peptides and methods of use
US8626951B2 (en) * 2007-04-23 2014-01-07 4Dk Technologies, Inc. Interoperability of network applications in a communications environment
JP2010526091A (ja) * 2007-04-30 2010-07-29 インテザイン テクノロジーズ， インコーポレイテッド 癌の処置のための生物学的な標的基の改変
GB0708864D0 (en) 2007-05-08 2007-06-13 Molmed Spa Cytokine Conjugate
CN101687911A (zh) 2007-05-16 2010-03-31 康久化学生物技术公司 抗病毒肽的半胱磺酸衍生物
US8850069B2 (en) * 2008-04-16 2014-09-30 Telefonaktiebolaget Lm Ericsson (Publ) Systems and methods for dynamically adaptive multi-way message conversion
ITRM20090102U1 (it) 2009-06-15 2010-12-16 Alfa Intes Ind Terapeutica Splendore S R L Ialuvit preparato per la stabilizzazione del film lacrimale, la cicatrizzazione corneale e il ripristino del contenuto salino della lacrima e osmoprotezione.
WO2011060104A2 (en) * 2009-11-10 2011-05-19 Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
US11673914B2 (en) * 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
WO2012045719A2 (en) 2010-10-05 2012-04-12 Molmed Spa New vascular targeting peptides
EP2707036A4 (en) 2011-05-09 2015-03-18 Allegro Pharmaceuticals Inc INTEGRIN RECEPTOR ANTAGONISTS AND METHOD FOR THEIR USE
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
CA3050904A1 (en) 2017-01-19 2018-07-26 Hampar L. Karageozian Therapeutic and neuroprotective peptides
JP7280619B2 (ja) 2017-06-19 2023-05-24 アレグロ ファーマシューティカルズ エルエルシー ペプチド組成物
EP3958915A4 (en) * 2019-04-22 2023-01-11 Allegro Ophthalmics, LLC COMPOSITIONS AND METHODS USABLE FOR THE TREATMENT OF DRY EYE
JP2022541851A (ja) * 2019-07-26 2022-09-27 アレグロ ファーマシューティカルズ エルエルシー 眼の非滲出型黄斑変性および他の障害を治療するためのペプチド
JP2023516431A (ja) * 2020-03-06 2023-04-19 アレグロ ファーマシューティカルズ エルエルシー ミトコンドリア機能の改善または機能障害の軽減のための治療

Also Published As

Publication number Publication date
MX2012005222A (es) 2012-08-15
US11666625B2 (en) 2023-06-06
NZ700296A (en) 2016-07-29
US20180193410A1 (en) 2018-07-12
US10307460B2 (en) 2019-06-04
ZA201204209B (en) 2013-08-28
JP5912201B2 (ja) 2016-04-27
BR112012011731A2 (pt) 2020-08-25
JP2015164957A (ja) 2015-09-17
RU2018101141A3 (es) 2021-10-12
AU2016222522B2 (en) 2018-02-22
CN102791296A (zh) 2012-11-21
EP3586879A1 (en) 2020-01-01
EP2504035A4 (en) 2013-07-17
AU2016222522A1 (en) 2016-09-22
CN105106934A (zh) 2015-12-02
CN110559422A (zh) 2019-12-13
IL248880B (en) 2021-03-25
JP2015147801A (ja) 2015-08-20
US9018352B2 (en) 2015-04-28
WO2011060104A2 (en) 2011-05-19
EP2504035B8 (en) 2019-06-05
US20200254055A1 (en) 2020-08-13
RU2642625C2 (ru) 2018-01-25
KR101988362B1 (ko) 2019-06-12
JP2013510863A (ja) 2013-03-28
IL219701A0 (en) 2012-07-31
US9872886B2 (en) 2018-01-23
EP2504035B1 (en) 2019-03-27
IL248880A0 (en) 2017-01-31
US10639347B2 (en) 2020-05-05
IL219701A (en) 2016-11-30
JP5912082B2 (ja) 2016-04-27
KR102237243B1 (ko) 2021-04-07
PL2504035T3 (pl) 2019-10-31
US20190343916A1 (en) 2019-11-14
RU2012118503A (ru) 2013-12-20
RU2018101141A (ru) 2019-02-20
KR20140015149A (ko) 2014-02-06
ES2730927T3 (es) 2019-11-13
HK1218075A1 (zh) 2017-02-03
AU2010319559A1 (en) 2012-05-31
US20110182989A1 (en) 2011-07-28
CN102791296B (zh) 2019-08-16
WO2011060104A3 (en) 2011-11-17
EP2504035A2 (en) 2012-10-03
KR20190068637A (ko) 2019-06-18
CA2780243C (en) 2019-12-03
JP5912202B2 (ja) 2016-04-27
US20160022763A1 (en) 2016-01-28
CA2780243A1 (en) 2011-05-19
NZ599899A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
MX346362B (es) Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.
MX2013012953A (es) Antagonistas de receptores de integrina y sus metodos de uso.
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
MY149731A (en) Compounds
CY1116989T1 (el) C-28 αμινες c-3 τροποποιημενων παραγωγων βετουλινικου οξεος ως αναστολεις hiv ωριμανσης
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
EA201390347A1 (ru) Лечение заболеваний
MX346608B (es) Compuestos de isoindol 5-sustituidos.
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MX2009000900A (es) Derivados de imidazolonas sustituidas, preparacion y usos.
MX2010009157A (es) Suministro mejorado de un agente terapeutico para tejidos oculares a traves de iontoforesis.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
IN2012DN03182A (es)
MX2009011281A (es) Benzimidazol y composiciones farmaceuticas del mismo.
MY163516A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
MX2014006004A (es) Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
MX2020005738A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
UA99787C2 (en) Lactams as beta secretase inhibitors
MY173890A (en) Crystalline naloxol-peg conjugate
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
MX2012007217A (es) Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.

Legal Events

Date Code Title Description
FG Grant or registration